Session Information
-
WCLC 2022
2022 World Conference on Lung Cancer
As an IASLC member, you can enjoy complimentary access to the presentations from the World Conference on Lung Cancer 2022. If you participated in the conference, kindly utilize the code "WCLC2022ACCESSFULL" to enter the virtual meeting and access the recordings.
Presentation Date(s):- August 6 - 9, 2022
- Total Presentations: 2015
All times listed are in Vienna, Austria Time, CEST (UTC+2:00)
PL - Plenary
IBS - Interactive Breakfast Session (in-person attendees only)
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
P - Posters
EP - ePosters
WS - Workshops
LA – Lectureship Awards
IS - Industry Symposium
August 5 Fri
Aug 5 Saturday
August 6 Sat
Aug 6 Sunday
August 7 Sun
Aug 7 Monday
August 8 Mon
Aug 8 Tuesday
August 9 Tue
Aug 9
-
+
OA03 - Molecular Targeted Treatments
- 14:30 - 15:40
- 8/07/2022
- Location: Hall C7
- Not for CME Credit
- Type: Oral
- Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
- Moderators:Andrew Ciupek, David R. Gandara
-
+
Session Moderator
15:32 - 15:40 | Presenter: Andrew Ciupek
- Abstract
Loading... -
+
Session Moderator
15:32 - 15:40 | Presenter: David R. Gandara
- Abstract
Loading... -
+
OA03.01 - Session Introduction
14:30 - 14:31 | Presenter: Andrew Ciupek
- Abstract
Loading... -
+
OA03.02 - Session Introduction
14:31 - 14:32 | Presenter: David R. Gandara
- Abstract
Loading... -
+
OA03.03 - Sotorasib in Combination with RMC-4630, a SHP2 Inhibitor, in KRAS p.G12C-Mutated NSCLC and Other Solid Tumors
14:32 - 14:42 | Presenter: Gerald Falchook
- Abstract
Loading... -
+
OA03.04 - Phase I A Study to Evaluate GDC-6036 Monotherapy in Patients with Non-small Cell Lung Cancer (NSCLC) with KRAS G12C Mutation
14:42 - 14:52 | Presenter: Adrian Sacher
- Abstract
Loading... -
+
OA03.05 - Tepotinib in Patients with MET Exon 14 (METex14) Skipping NSCLC: Primary Analysis of the Confirmatory VISION Cohort C
14:52 - 15:02 | Presenter: Michael Thomas
- Abstract
Loading... -
+
OA03.06 - CodeBreaK 100/101: First Report of Safety/Efficacy of Sotorasib in Combination with Pembrolizumab or Atezolizumab in Advanced KRAS p.G12C NSCLC
15:02 - 15:12 | Presenter: Bob T. Li
- Abstract
Loading... -
+
OA03.07 - Safety and Efficacy of D-1553 in Patients with KRAS G12C Mutated Non-Small Cell Lung Cancer: A Phase 1 Trial
15:12 - 15:22 | Presenter: Shun Lu
- Abstract
Loading... -
+
OA03.08 - Discussant
15:22 - 15:32 | Presenter: Helena Linardou
- Abstract
Loading... -
+
OA03.09 - Live Q&A
15:32 - 15:40
- Abstract
Loading...
-
+
P2.12 - Tumor Biology and Biomarkers - Immune Biology & Immunotherapy
- 17:15 - 19:15
- 8/08/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: Regular Poster
- Track: Tumor Biology and Biomarkers - Immune Biology & Immunotherapy
-
+
P2.12-03 - External Validation of a Novel CT-Based Prognostic Radiomic Signature in Patients With Metastatic NSCLC in SWOG S0819 Phase III Randomized Trial
Presenter: Laurent Dercle- Abstract
Loading...
-
+
MA13 - Update on ROS1 Inhibitors and New Pathways
- 12:00 - 13:00
- 8/09/2022
- Location: Hall C7
- Not for CME Credit
- Type: Mini Oral
- Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
- Moderators:Lorenza Landi, Jii Bum (Joy) Lee
-
+
MA13.08 - A Phase 1 Trial of Sapanisertib and Telaglenastat (CB-839) in Patients With Advanced NSCLC (NCI 10327): Results from Dose Escalation
12:32 - 12:37 | Presenter: Jonathan Riess
- Abstract
Loading...